Abstract
Streptococcus pneumoniae is a polysaccharide-encapsulated bacterium. The capsule thickens during blood invasion compared with the thinner capsules observed in asymptomatic nasopharyngeal colonization. However, the underlying mechanism regulating differential CPS expression remains unclear. CPS synthesis requires energy that is supplied by ATP. Previously, we demonstrated a correlation between ATP levels and adenylate kinase in S. pneumoniae (SpAdK). A dose-dependent induction of SpAdK in serum was also reported. To meet medical needs, this study aimed to elucidate the role of SpAdK in the regulation of CPS production. CPS levels in S. pneumoniae type 2 (D39) increased proportionally with SpAdK levels, but they were not related to pneumococcal autolysis. Moreover, increased SpAdK levels resulted in increased total tyrosine kinase Cps2D levels and phosphorylated Cps2D, which is a regulator of CPS synthesis in the D39 strain. Our results also indicated that the SpAdK and Cps2D proteins interact in the presence of Mg-ATP. In addition, in silico analysis uncovered the mechanism behind this protein–protein interaction, suggesting that SpAdK binds with the Cps2D dimer. This established the importance of the ATP-binding domain of Cps2D. Taken together, the biophysical interaction between SpAdK and Cps2D plays an important role in enhancing Cps2D phosphorylation, which results in increased CPS synthesis.
Pneumococcal disease: enzyme interaction promotes thickening of defensive bacterial capsule
A physical interaction between two key enzymes explains how the bacterium responsible for causing pneumococcal disease thickens its external capsule during infection of the bloodstream. A team led by Dong-Kwon Rhee from Sungkyunkwan University in Suwon, South Korea, studied strains of Streptococcus pneumoniae expressing varying levels of an enzyme that helps maintain the proper balance of cellular energy. They found that this enzyme stimulated the production of sugar chains that coat the outside of the bacterial capsule by binding and activating an intermediary enzyme involved in the synthesis of these sugar chains. Since the capsule is critical in warding off the human immune response, the findings suggest that drugs designed to disrupt the enzyme-mediated induction of capsule formation could help prevent or treat pneumococcal disease.
Introduction
Streptococcus pneumoniae (a pneumococcus) colonizes the human respiratory tract as a commensal. It is also responsible for local infections and a number of invasive diseases such as pneumonia, sepsis, and meningitis1–3. More than 90 serotypes of pneumococcus have been reported. Migration through tissue barriers and subsequent adaptation to diverse host niches have converted an apparently harmless commensal into an invasive pathogen. This adaptation process is multifactorial and occurs in an extremely regulated manner4.
Some pneumococci are encapsulated by capsular polysaccharides (CPSs), which are important virulence factors that protect bacteria from the host immune system5. The ability of S. pneumoniae to control CPS production plays an important role in pneumococcal survival in various host niches6. However, the mechanism underlying the regulation of differential CPS production is not properly understood7. Previous studies showed that, with the exception of type 37, pneumococcal CPS production mostly relies on the cps locus positioned between the dexB and aliA genes8,9. In the pneumococcal cps locus, the first four genes are highly conserved and are designated cpsA (transcription activator), cpsB (phosphotyrosine-protein phosphatase), cpsC (polysaccharide export protein), and cpsD (autophosphorylating tyrosine kinase)10–12. The genes downstream of cpsD are serotype specific7 and are mainly responsible for polymerization and dissemination of polysaccharide13. In the type 2 pneumococcal cps locus, these genes are denoted as cps2A, cps2B, cps2C, and cps2D14. Cps2B, Cps2C, and Cps2D constitute a phosphoregulatory system that partly modulates CPS levels10–12.
In all organisms including pneumococci, intracellular ATP regulation is considered one of the most important factors for survival15,16. S. pneumoniae adenylate kinase (SpAdK) was crystalized and found to be essential for pneumococcal growth3. SpAdK catalyzes the conversion between adenylate nucleotides: Mg · ATP + AMP ↔ Mg · ADP + ADP17. Furthermore, SpAdK is essential for pneumococcal viability3. BLAST searches indicated a highly conserved adk sequence among various pneumococcal serotypes3, suggesting that the adk gene may be a potent target for developing serotype-independent chemotherapeutics.
Although antimicrobial therapies and conjugate vaccines are available, S. pneumoniae continues to be the etiologic agent of various diseases. Intensive efforts are focused on encouraging the development of alternative pneumococcal vaccine approaches that overcome the drawbacks of the present strategies while maintaining efficacy. CPS is one of the most significant pneumococcal virulence factors both in the context of disease pathogenesis and therapeutic importance. This is because all commercially available pneumococcal vaccines have been developed on the basis of capsular serotypes18. The structural and chemical variability of capsules among different pneumococcal strains is responsible for the fundamental limitations of CPS-based vaccines, including serotype-specific protection, capsular switching, and serotype replacement19–21. The capsule is an energetically expensive structure to produce, because the carbohydrates that are assimilated could otherwise be used in glycolysis to facilitate replication22. Therefore, it is expected that the capsule biosynthesis machinery is linked with pneumococcal metabolic regulatory systems23.
Previously we showed that the fucose-inducible conditional encapsulated (S type) adk mutant was not able to grow, as well as the isogenic non-encapsulated (R type) adk mutant, possibly due to the excess ATP required for CPS production. SpAdK expression increased in a serum dose-dependent manner3. Although the reduced virulence of the adk mutant compared with the wild-type (WT) was also observed in mice3, the underlying mechanism remains unknown. On the other hand, maximum expression of CPS was observed during systemic virulence6. Expression of cps2A was also induced in the presence of serum24. Thus, we studied the role of SpAdK in pneumococcal CPS synthesis.
Our results indicated that S. pneumoniae CPS increased proportionally with SpAdK levels. In addition, the increase in SpAdK expression was correlated with phosphorylation of Cps2D, a regulator of CPS synthesis. Moreover, SpAdK interacted physically with Cps2D in the presence of Mg-ATP. The autophosphorylation mechanism of CpS2D and interaction of SpAdK with Cps2D were further supported using in silico analyses.
Materials and methods
Ethical statement and raising antibodies
This is described in the Supplementary Information
Bacterial strains, culture conditions, cloning, and protein purification
All reagents used for bacterial culture were purchased from Difco BD (NJ, USA). The bacterial strains and plasmids used in this study are listed in Table 1. Non-encapsulated S. pneumoniae serotype 2 CP120025, R6 (a derivative of D39), and TTL04 were cultured in casitone-tryptone-based medium (CAT). Encapsulated S. pneumoniae serotype 2 D39 (NCTC7466)26 and TTL01 were cultured in Todd–Hewitt broth containing yeast extract (THY) or THY agar containing 5% (v/v) sheep blood as previously described27. The Escherichia coli strain was cultured in Luria broth (LB) medium. Optical densities at A550 or A600 were used to measure the growth of S. pneumoniae or E. coli, respectively.
Table 1.
Strains/plasmids | Relevant characteristics | Antibiotic resistance | Reference |
---|---|---|---|
Strains | |||
S. pneumoniae | |||
D39 | Encapsulated, type 2 | 26 | |
TTL01 | D39 PfcsK::adk carrying an ermAM cassette | ERY | 3 |
CP1200 | Non-encapsulated derivative of Rx1 malM511-str1 | 25 | |
TTL04 | CP1200 PfcsK::adk carrying an ermAM cassette | ERY | 3 |
R6 | Non-encapsulated derivative of D39, no cpsBCD | 26 | |
E. coli | |||
BL21(DE3) | gal (cI ts857 ind1 Sam7 nin5 lacUV5-T7 gene 1) | Novagen | |
Rosetta2 | Expresses seven rare tRNAs | Novagen | |
Plasmids | |||
pET32b | 5899 bp; E. coli plasmid | AMP | Novagen |
pCPS01 | His-tagged cps2B in pET32b | AMP | This study |
pCPS02 | His-tagged cps2C in pET32b | AMP | This study |
pGST-parallel 2 | 5038 bp; E. coli plasmid | AMP | 55 |
pHis-parallel 2 | 5517 bp; E. coli plasmid | AMP | 55 |
pGST-ADK | GST-tagged SpAdK in pGST-parallel 2 | AMP | This study |
pCPS03 | His-tagged cps2D in pHis-parallel 2 | AMP | This study |
pCPS04 | His-tagged cps2D-3Y3E in pHis-parallel 2 | AMP | This study |
pCPS05 | His-tagged cps2D-GA-KK in pCPS03 | AMP | This study |
pCPS06 | His-tagged cps2D-GA-KK in pCPS04 | AMP | This study |
ERY erythromycin, AMP ampicillin
Cloning and protein purification methods are described in detail in the Supplementary Information.
Fucose-inducible conditional adk mutant strain construction
A conditional adk mutant controlled by a fucose promoter in either S (smooth, encapsulated/TTL01) or R (rough, non-encapsulated/TTL04) type strains (Table 1) was constructed by substituting the adk promoter with the PfcsK inducible promoter in the pneumococcal chromosome to allow fucose regulation of SpAdK levels as described previously3.
Preparation of total CPS
Total CPS was prepared from pneumococci grown in THY broth as previously described28. Pneumococci were harvested at A550 = 0.3 using centrifugation and rinsed twice with phosphate-buffered saline (PBS) before resuspending in PBS. The samples were calibrated to the same optical density at A550 to obtain the same concentration of bacteria. Subsequently, the pellets were resuspended in 500 μL of buffer A (Tris-Cl pH 7.0 and 1 mM MgSO4). The pellets were treated with 0.1% (w/v) sodium deoxycholate (DOC) at 37 °C for 15 min. Next, mutanolysin (100 U), DNase I (50 µg), and RNase A (50 µg) were added. The samples were slightly inverted at 37 °C for 18 h. Finally, the total CPS sample was treated with proteinase K (50 µg) and incubated at 56 °C for 4 h prior to storage at –20 °C. The samples were thawed on ice before the CPS quantification assay. All reagents used in this study were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Quantification of pneumococcal CPS by the phenol–sulfuric method
The amount of CPS was determined by a phenol–sulfuric assay. CPS samples were plated onto 96-well microplates, followed by addition of 150 µL of 95% H2SO4 (Duksan Pharmaceutical Co., Ansan, Korea) and 30 µL of 5% phenol (pH 8.2; Sigma-Aldrich). The mixture was incubated at 100 °C for 10 min, followed by cooling to 25 °C before measuring the optical density at A490. Because the S. pneumoniae serotype 2 CPS is composed of 2 U of d-glucose, 3 U of l-rhamnose, and 1 U of d-glucuronic acid10, a sugar solution of 2 U of d-glucose, 3 U of l-rhamnose, and 1 U of d-glucuronic acid (Sigma-Aldrich) was used as a standard control.
Analysis of pneumococcal CPS using enzyme-linked immunosorbent assay (ELISA)
To measure total CPS, an indirect ELISA was performed with slight modifications as previously described29. S. pneumoniae was incubated in THY to A550 = 0.3. After centrifugation at 4000 × g for 10 min, the bacterial pellets were washed three times with PBS. The pellets from 1 mL of culture were suspended in 500 µL of PBS, and the optical density was adjusted to obtain similar amounts of bacteria. Next, the samples were heat killed at 65 °C for 20 min. After cooling to room temperature, 20 μL of heat-killed samples was coated onto plates containing 80 µL of PBS and immobilized for 4 h at 4 °C. The samples were further incubated with 1% (w/v) bovine serum albumin (Sigma-Aldrich) to block nonspecific binding. After washing with TPBS (PBS containing 0.05% Tween-20; Sigma-Aldrich), 100 μL of serotype 2 CPS rabbit antiserum (1:1000 in TPBS; Statens Serum Institut, Copenhagen, Denmark) was added to the samples and incubated at 25 °C for at least 90 min. Next, the plate was rinsed with TPBS three times. The samples were further incubated with secondary rabbit antibody conjugated to horseradish peroxidase (HRP; 1:10,000) at room temperature for 1 h. Next, the plate was washed with TPBS. The colorimetric substrate 3,3′,5,5′-tetramethylbenzidine (Biosciences BD, NJ, USA) was added to the wells, and A650 was measured using an ELISA reader (Softmax Pro 5.4).
Western blotting
S. pneumoniae was grown exponentially in THY and lysed in lysis buffer (50 mM Tris-Cl, pH 8.0, 1 mM DTT, and 0.1% Triton X-100). Total protein was collected, run on a sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel (10–20%), and transferred onto a 0.2-µm polyvinylidene difluoride (PVDF) membrane (Merck Millipore, MA, USA). The membrane was blocked with 3% (w/v) skim milk in TTBS (Tris-buffered saline [TBS] containing 0.1% Tween-20; Sigma-Aldrich) for 2 h at room temperature. Next, the membrane was probed overnight at 4 °C with polyclonal mouse sera raised against SpAdK, Cps2B, Cps2C, Cps2D, PsaA, and PspA appropriately diluted in TTBS. Next, the membrane was probed with HRP-conjugated anti-mouse immunoglobulin G (IgG) (1:10,000 in TTBS) for 1 h. The proteins were visualized by adding West-Q Pico ECL Solution (GeneDEPOT, TX, USA), captured using a Chemiluminescence Imaging System (Davinch-Chemi, Seoul, Korea), and analyzed using densitometry with the ImageJ software 1.4.3 (NIH, USA).
Immunoprecipitation (IP)
IP and western blotting were performed as previously described11. Pneumococcal D39 WT lysate (100 µg; obtained as described for western blotting) was incubated with 5 µL of antibodies against SpAdK, Cps2D, or AdhE (negative control) at 4 °C for 4 h with gentle agitation. The mixture was mixed with 20 µL of Protein A/G PLUS Agarose (Santa Cruz Biotech, CA, USA) and gently agitated overnight at 4 °C. The beads were collected and washed six times in lysis buffer. IP proteins were detached from the beads by adding 50 µL of 2 × SDS-PAGE loading buffer and boiled at 100 °C for 4 min. The supernatant (20 µL) was loaded onto 15% SDS-PAGE gels and analyzed using western blotting with SpAdK, CpsD, or AdhE antibodies.
Bio-layer interferometry (BLI)
BLI experiments were performed using a Blitz system (ForteBio, CA, USA). His6-Cps2D WT or 3Y3E mutant protein (1 μM) were immobilized on Ni-NTA sensors (ForteBio, CA, USA). Binding of SpAdK was monitored by adding various concentrations of glutathione S-transferase (GST)-SpAdK (2.5–50 μM) in buffer D (250 mM NaCl, 50 mM Tris-HCl, pH 7.5, and 1 mM DTT) in the absence or presence of 5 mM Mg-ATP. BLI experiments with Cps2D GK-AA and GK-AA/3Y3E were similarly performed in buffer D. GST protein was used as a negative control, and background signals from GST and sensors were subtracted before binding analysis. The experiments were repeated at least twice. Kd values were determined using steady-state analysis with GraphPad Prism (GraphPad Software Inc, CA, USA).
Fluorescence microscopy
For visualization of fluorescein isothiocyanate (FITC)-labeled CPS, S. pneumoniae was grown exponentially in THY broth, and bacteria were collected by centrifugation. Subsequently, the cells were fixed with 5% formaldehyde (Sigma-Aldrich) by incubating for 15 min, rinsed twice with distilled water, and resuspended in 0.1 volume of the original culture volume of PBS. The suspension (100 µL) was cross-reacted with the type 2 rabbit antiserum (1:500 in PBS; Statens Serum Institut) for 90 min and probed with anti-rabbit FITC (1:1000 in PBS; Sigma-Aldrich) for 1 h. Samples (10 µL) were mounted on a slide, covered with 50% glycerol, and visualized using a confocal microscope (LSM 510; Carl Zeiss; Oberkochen, Germany).
Phos-tagTM acrylamide gel and western blotting
S. pneumoniae was grown exponentially in THY and lysed in lysis buffer. Total protein was collected and run on a Phos-tagTM acrylamide gel (10% SDS-PAGE supplemented with 25 µM Phos-tagTM AAL-107 [Wako Pure Chemical, Osaka, Japan] and 100 µM MnCl2 [Sigma-Aldrich]). Next, the gel was soaked in transfer buffer with 1 mM EDTA with light agitation for 10 min to eliminate Mn2+ from the gel. Next, the gel was briefly rinsed with transfer buffer without EDTA once and re-soaked in transfer buffer (no EDTA). The proteins were transferred from the gel to a PVDF membrane (Merck Millipore). After transfer, the membrane was blocked with 3% (w/v) skim milk (Merck) in TTBS for 1 h at room temperature. The membrane was washed with TTBS for 30 min and probed with total Cps2D antibody (1:1000 dilution in TTBS) overnight at 4 °C. The membrane was again washed with TTBS for 40 min and probed with HRP-conjugated anti-mouse IgG (1:10,000 in TTBS) for 1 h. The proteins were visualized by adding West-Q Pico ECL Solution, captured using a Chemiluminescence Imaging System, and analyzed using densitometry with ImageJ software.
Sequence analysis and structural modeling of the SpAdK and Cps2D proteins
Cps2D is a tyrosine kinase of approximately 226 amino acids and no three-dimensional (3D) structural information to date. To predict the 3D structure of full-length Cps2D protein (UniProtKB ID: Q9ZII6), we utilized MOE, I-TASSER30, and SwissModel servers. These packages predicted similarly folded structures for Cps2D except for the C-terminus flexible tyrosine-rich region. Based on sequence identity and coverage, the C-terminus was not properly predicted by MOE and SwissModel. However, the models provided by I-TASSER (using a threading technique) were properly folded and retained the C-terminus tail, which is necessary for Cps2D phosphorylation. The structure of SpAdK was previously studied in open and closed conformations using X-ray crystallography (PDB ID: 4NU0, 4NTZ). Both conformers were retrieved from PDB and prepared for docking analyses.
Docking simulations
After thoroughly investigating the structure of Cps2D, ATP, and ADP were docked into the active site suggested by I-TASSER and confirmed through sequence and structural alignments with other bacterial-encoded tyrosine kinases. The induced fit docking method implemented in MOE was used to predict the binding ability and affinity of phospho-adenosine to the active site of Cps2D. Before docking, the predicted model was optimized using the protein preparation tool in MOE. Partial charges and hydrogens were added where needed. The structure was relaxed and energy minimized to remove steric clashes, keeping the backbone atoms fixed and the side-chains flexible using Amber10: EHT force field. The ligands were docked into the suggested active site using the default induced fit docking protocol in MOE.
To evaluate the possible mechanism of Cps2D tyrosine phosphorylation and its interaction with SpAdK, we divided the protein–protein docking simulation into two steps. First, to understand the autophosphorylation mechanism, Cps2D was docked with itself using ZDOCK31, PatchDock32 online server, and MOE. Second, to understand the binding mechanism of Cps2D and SpAdK as suggested by our empirical results, they were docked using the same protocols. The docked conformers provided by ZDOCK and PatchDock were submitted to FireDock for refinement33. FireDock simultaneously targets the problem of flexibility and scoring of solutions produced by the fast, rigid body docking algorithms of PatchDock and other servers. FireDock refines and scores a large set of complexes selected from input files and sorts them according to their minimum global energy. Interface analyses were performed in MOE, UCSF Chimera, and PyMol34, whereas images were generated in MOE and PyMol. Structure and sequence alignments and comparisons were performed in MOE and BioEdit.
Statistical analysis
Statistical analysis between the different experimental groups in the phenol–sulfuric acid assay, ELISA, western blotting, adherence, survival, and phagocytic activity assays were calculated using a one-way analysis of variance (ANOVA) (Duncan’s method, non-parametric). ELISA data are expressed as the mean ± standard deviation (SD; n = 3). A non-parametric, two-tailed value of P ≤ 0.05 (*), P ≤ 0.01 (**), or P ≤ 0.001 (***) was considered statistically significant.
Results
Increase in pneumococcal CPS levels by SpAdK
SpAdK was previously shown to be essential for pneumococcal growth. To confirm that SpAdK expression is essential for CPS synthesis, we used the encapsulated TTL01 strain, which is under the control of a fucose promoter3, and analyzed SpAdK expression and CPS levels under various concentrations of fucose (0, 0.1, 0.5, and 1.0%). Fucose can control SpAdK levels in the TTL01 strain but not in D39 WT (Fig. 1a), indicating that fucose does not affect D39 WT SpAdK levels. These results agreed with our previous findings, suggesting that differences in conditional adk mutant strains were due to different SpAdK levels3.
To quantify CPS levels, the phenol–sulfuric assay showed that total CPS levels of TTL01 significantly increased at 1.0% compared with 0.1% fucose (Fig. 1b). Consistently, ELISA results also showed a substantial increase in TTL01 CPS levels after supplementing with 1.0% fucose compared with 0.1% fucose-treated cells (Fig. 1c). These findings indicate that CPS levels were significantly increased in the TTL01 strain after treating with 1% fucose compared with WT (Figs. 1b, c). The D39-derived non-encapsulated S. pneumoniae R6 strain (∆cpsBCD) was used as a negative control in this experiment. Almost no CPS was detected in R6 samples regardless of fucose concentration (Fig. 1c). To exclude the possibility of fucose affecting CPS quantitation assays, D39 WT was incubated with various concentrations of fucose (0, 0.1, 0.5, and 1.0%) and CPS levels were measured. We found that fucose did not show any significant effects on CPS levels (data not shown).
To confirm the dependence of CPS on SpAdK levels, the R6, D39 WT, or TTL01 strains were grown to log phase in varying concentrations of fucose. Next, the harvested bacterial pellets were treated with CPS antibody and visualized using confocal microscopy. The TTL01 strain at 1.0% fucose showed stronger fluorescence than 0.1% fucose, but D39 WT did not show any significant difference in fluorescence intensity after fucose supplementation (Fig. 1d). We used non-encapsulated S. pneumoniae R6 as a negative control and almost no FITC-CPS signal was detected at any level of fucose.
SpAdK increases Cps2D levels
The autophosphorylating tyrosine kinase Cps2D supplies ATPs that provide energy during CPS synthesis10,35. SpAdK regulates ATP levels in S. pneumoniae3 and increases CPS levels. However, the underlying mechanism remains unclear. To elucidate SpAdK-mediated cps locus regulation, the expression profiles of Cps2B, Cps2C, and Cps2D were compared between the D39 WT and TTL01 strains after fucose treatment using specific antibodies raised against these proteins (Supplementary Information). In the TTL01 strain, expression levels of Cps2B and Cps2C did not change, but Cps2D levels increased significantly along with SpAdK levels (Fig. 2). Additionally, fucose did not affect Cps2B, Cps2C, and Cps2D levels in D39 WT (Fig. 2). Moreover, SpAdK did not affect autolysin (LytA) and surface protein (PsaA and PspA) expression levels in both D39 WT and TTL01 strains (Fig. 2).
SpAdK enhances Cps2D phosphorylation
Cps2D contains an ATP-binding domain and requires ATP to autophosphorylate its C-terminus tyrosine cluster35. Moreover, the increase in Cps2D levels is directly proportional to SpAdK levels (Fig. 2). To address the effect of SpAdK on the phosphorylation of Cps2D, Phos-tagTM SDS-PAGE was used to determine phosphorylated Cps2D levels, because the Phos-tagTM complexed with Mn2+ can detect phosphorylated proteins in SDS-PAGE36. After densitometry analysis, the phosphorylated Cps2D protein was found to increase proportionally with SpAdK levels in the TTL01 strain (Fig. 3a, b). Moreover, phosphorylated Cps2D levels in TTL01 after 1% fucose treatment were significantly higher than in D39 WT (Fig. 3a, b). To test whether fucose affects protein levels, D39 WT was incubated with the highest fucose concentration (1.0%). However, 1.0% fucose did not affect the Cps2D protein level. Thus, the difference in proteins levels was due to SpAdK levels and not fucose. These results indicate that the interaction between SpAdK and the Cps2D proteins enhanced phosphorylation of Cps2D and resulted in increased CPS levels.
SpAdK physically interacts with Cps2D
As SpAdK modulates Cps2D levels, we analyzed whether SpAdK interacts with Cps2D using an IP assay with antibodies against SpAdK, Cps2D, and AdhE (as a negative control), followed by western blotting. IP results showed that SpAdK physically interacts with Cps2D (Fig. 4). The AdhE antibody did not show any interaction with SpAdK and Cps2D (Fig. 4). Moreover, the IgG proteins were always detected in the IP studies, including SpAdK, Cps2D, and AdhE (control). However, the target protein was detected only for IP: SpAdK and IP: Cps2D samples, indicating a physical interaction between SpAdK and Cps2D.
Biophysical characterization of the SpAdK–Cps2D complex
Mutating tyrosine (Y) to glutamic acid (E) in the C-terminus tyrosine cluster was previously used in in vitro and in vivo studies to determine protein phosphorylation37,38. To investigate the effect of Cps2D phosphorylation on its interactions with SpAdK, we prepared a triple phosphomimetic mutant, 3Y3E, where three tyrosine residues (Y215, Y218, and Y221) in the tyrosine cluster of Cps2D were mutated to glutamic acid. The WT and the 3Y3E mutant of Cps2D were purified to homogeneity (Fig. 5a). Quantitative binding analysis using BLI revealed that SpAdK binds to both WT and 3Y3E in the presence of Mg-ATP with apparent Kd values of 31 ± 5 μM and 40 ± 17 μM, respectively (Fig. 5b-d).
The ATP-binding domain of Cps2D contains conserved glycine (G) 48 and lysine (K) 49 amino-acid residues that are shared with other bacteria35. To determine whether the ATP-binding domain of Cps2D plays any role in the interaction with SpAdK, we prepared double mutants of G48 and K49 mutated to alanine (A) in the background of Cps2D/WT and Cps2D/3Y3E termed GK-AA and GK-AA/3Y3E, respectively. SpAdK did not bind to either GK-AA or GK-AA/3Y3E, suggesting that ATP-binding residues have a crucial role in the SpAdK–Cps2D interaction (Fig. 5c, d). These results show that phosphorylation of the tyrosine cluster of Cps2D does not interfere with its interaction with SpAdK, whereas the ATP-binding capability of Cps2D is critical in mediating the interaction between Cps2D and SpAdK.
In silico structural analysis of Cps2D and the Cps2D–SpAdK interaction mechanism
Based on our empirical results, we proposed a structural model that describes autophosphorylation of Cps2D and its interaction with SpAdK. The optimized 3D structure of Cps2D is a correctly folded protein that shares domain organization with the previously reported BY-kinases (bacterial tyrosine kinases), CapB39 and Wzc40. Structural and sequence alignment confirmed that Cps2D is a P-loop-containing protein kinase with Walker A41 nucleotide-binding motifs in its core region. The loop between α3 and β1 containing –GEGKS– residues corresponds to the defined P-loop, which is involved in ATP binding (Fig. 6a). This loop establishes typical interactions with docked ADP. Similar results were previously reported39. The interaction between ADP and bound Mg2+ ions is further stabilized by the DxD motif (containing aspartic acid [D] 70 and aspartic acid [D] 73, located 20 amino acids downstream of the Walker A motif) and D152 of the Walker B motif (Fig. 6b). Structural alignment suggested that Cps2D shares domain organization and sequence identity with E. coli Wzc (RMSD 1.02) more than the Staphylococcus aureus CapB kinase (RMSD 1.5; Fig. 6c).
In this study, we reported that SpAdK establishes direct contact with Cps2D and enhances its phosphorylation levels. To further elucidate this mechanism, we proposed a possible interaction mechanism between SpAdK and the Cps2D dimer bound to ATP. It was reported that the C-terminus of S. aureus CapA acts as an activator for the CapB tyrosine kinase and exists in the chimeric “CapA/CapB” form39. We also found that WT SpAdK and its triple mutant 3Y3E interact with purified Cps2D, suggesting a similar role for the enzymatic activity of Cps2D as CapA in CapA/CapB. However, there are some discrepancies that cannot be explained by our trimeric complex.
Overall, the proposed model suggests that SpAdK stabilizes the interface between oligomeric Cps2D. Charged and uncharged polar residues are mainly involved at the heterotrimeric interface (Fig. 7a). The “V”-shaped helical motif of SpAdK that anchors the two Cps2D dimers was reported to be involved in AMP binding3. As SpAdK regulates ATP levels, we theorize that Pi released through this motif may possibly be involved in the phosphorylation of Cps2D. Moreover, the polar residues in this motif establish direct contact with ATP and its binding interface on one of the bound Cps2D monomers (Fig. 7b).
Discussion
AdK reversibly catalyzes the nucleotide phosphoryl exchange reaction17. The role of AdK in the regulation of adenine nucleotide homeostasis is well established17. Pyruvate oxidase has a direct influence on ATP production and is a crucial link between pneumococcal metabolism and CPS synthesis18. In this study, we report for the first time that pneumococcal capsule synthesis is directly regulated by SpAdK through its interaction with the Cps2D protein. Thus, the amount of ATP required for CPS synthesis in the encapsulated adk mutant strain might retard growth compared with the non-encapsulated strain (Supplementary Figure S1).
Tyrosine kinases are crucial for CPS regulation42,43. For instance, a mutant of the tyrosine kinase, Wzc, of the Gram-negative E. coli serotype K30 impairs the production levels of its high-molecular-weight capsule44. Furthermore, the ExoP mutant of Sinorhizobium meliloti produces less succinoglycan (of the exopolysaccharide) by altering ATPase activity45. The CpsD of S. pneumoniae is comparable to the Wzc, CapB, and YwqD proteins present in E. coli, S. aureus, and Bacillus subtilis, respectively46. Cps2D is essential for CPS synthesis, and a cps2D deletion mutant showed reduced CPS levels14. Pneumococcal capsule synthesis is driven by the ATP generated by Cps2D, whereas SpAdK regulates ATP levels in S. pneumoniae. Therefore, there may be a possibility that SpAdK increases Cps2D levels and ultimately results in increased ATP-mediated CPS synthesis. Our results indicate that increased SpAdK levels led to a significant increase in total and phosphorylated Cps2D levels, which eventually resulted in enhanced CPS production (Figs. 1, 2, and 3). A previous report showed that the deletion of cps2B resulted in increased tyrosine-phosphorylated Cps2D levels that enhanced CPS production levels in S. pneumoniae D3914. This is consistent with a study by Weiser et al.47 that showed that reduced environmental oxygen levels resulted in increased pneumococcal capsule production via increased phosphorylation of Cps2D. Although a recent study suggested that the levels of Cps2D phosphorylation are not a determinant for CPS regulation, they did not exclude the role of Cps2D in CPS synthesis48. However, it was also reported that autophosphorylation of Cps2D negatively influences pneumococcal CPS production6. To date, an underlying mechanism that resolves these conflicting results remains to be elucidated.
CPS is required for asymptomatic pneumococcal colonization of the respiratory tract or for invasive diseases12. During colonization, S. pneumoniae expresses low levels of CPS (transparent type) to enhance the exposure of cell surface proteins and promote binding to epithelial cells49. During high oxygen availability, S. pneumoniae D39 reduces Cps2D phosphorylation, resulting in reduced CPS levels48. In contrast, S. pneumoniae expresses high CPS levels (opaque type) during systemic infection to evade complement-mediated opsonophagocytosis12. S. pneumoniae serotype 6A opaque variants show enhanced Cps6aD expression compared with transparent variants47. Therefore, survival of S. pneumoniae throughout various invasive steps requires modulation of CPS expression to adapt to different niches. How pneumococci manipulate capsular gene expression levels between colonization (thin capsule) and invasion (thick capsule) remains unclear. SpAdK expression was shown to be induced by serum3. In addition, our results show that SpAdK increases CPS levels by upregulating Cps2D. Accordingly, transcript levels of the cps locus were also elevated by SpAdk (Supplementary Figure S2). Pneumococci present in the bloodstream produce a thick capsule. Thus, pneumococci may induce expression of specific enzymes that subsequently increase ATP levels and CPS synthesis. This warrants further investigation of whether SpAdK is produced by pneumococci in the blood to supply ATP for energy metabolism and CPS synthesis.
CPS is known to inhibit adherence to host cells50 and protect bacteria from the host immune system. S. pneumoniae with a thin capsule show higher levels of cell wall phosphorylcholine and surface proteins, which allows stronger binding to epithelial cells51,52. Adherence of the TTL01 strain to the macrophage RAW 264.7 and HEp-2 cells significantly decreased proportionally to SpAdK levels (Supplementary Figure S3). Additionally, protein levels of PsaA and PspA in the TTL01 strain did not show any significant difference from D39 WT (Fig. 2). Therefore, SpAdK appears to affect multiple factors by increasing the surface energy charge of pneumococci and CPS levels that may play important roles in adherence. CPS also inhibits phagocytosis53 because CPS expression increases resistance to complement C3 deposition and subsequently to phagocytosis by neutrophils51,54. To confirm the dependence of CPS on SpAdK, the effect of SpAdK on the phagocytic activity of macrophages was analyzed. Phagocytosis was inhibited at high SpAdK expression levels and high CPS levels (Supplementary Figure S4).
To explore the underlying mechanism behind SpAdK-mediated CPS regulation, we performed IP assays to assess if SpAdK directly interacts with Cps2D. Our results showed a physical interaction between SpAdK and Cps2D (Fig. 4). However, as the molecular sizes of SpAdK (approximately 27 kDa) and Cps2D (27 kDa) are quite close to that of the IgG light chain (25 kDa), we could not get satisfactory IP results with western blotting even after repeated efforts (Fig. 4). To gain insights into the SpAdK–Cps2D interaction and to further confirm our IP data, we performed a BLI experiment with purified proteins. This showed that SpAdK can interact with the Cps2D protein in the presence of Mg-ATP (Fig. 5). However, it was not necessary to add exogenous Mg-ATP during the IP assay to support the interaction of SpAdK and Cps2D because pneumococcal cell lysate, a great source of Mg-ATP, was used. Moreover, the importance of the ATP-binding domain of Cps2D in this interaction was also established.
To model the signaling mechanisms of proteins in a protein network, a molecular docking study was utilized to predict the preferred orientation of the two interacting chemical species. The in silico structural similarities and domain organizations indicated that, like other BY-kinases, Cps2D may have a similar role in CPS production (Fig. 6), which agrees with previous findings. In line with the previously reported autophosphorylation mechanism of BY-kinases, our model also suggests a similar mechanism (Supplementary Figure S5). The tyrosine-rich motif located at the distant C-terminus, which is involved in autophosphorylation, fits near the ATP-binding site of the adjacent Cps2D. The proposed model is in line with our mutational and biophysical analyses, which showed that mutating the conserved ATP-binding residues, G48 and K49, abolished the Cps2D–SpAdK interaction (Fig. 7). As the BLI analyses were performed in the presence of Mg-ATP, mutating the two conserved residues dismantled the ATP interaction and dissociated the interaction with SpAdK. BLI analyses suggest that Cps2D binds SpAdK in the presence of Mg-ATP regardless of the presence or absence of the C-terminus tyrosine cluster. This was supported by our model, which suggests that Cps2D does not interact with SpAdK through its C-terminus. Cumulatively, these results provide a mechanism of the Cps2D-ATP/ADP binding, Cps2D autophosphorylation, and the role of SpAdK in the regulation of Cps2D.
Based on their regulatory role in polysaccharide production, BY-kinases were classified as polysaccharide co-polymerases, supporting the polymerase function of the membrane polysaccharide assembly machinery. However, the in-depth mechanism by which BY-kinases interact with this machinery remains unclear. Our study may provide a significant contribution to understanding the underlying mechanism behind BY-kinase-mediated regulation of capsule production.
Altogether, our findings indicate that cellular ATP and total CPS levels increase proportionally to SpAdK levels, establishing the involvement of SpAdK in CPS production. Furthermore, the involvement of SpAdK in CPS synthesis appears to be mediated by Cps2D phosphorylation, a key regulator in the CPS biosynthesis pathway. Based on the significance of CPS in pneumococcal systemic virulence, it would be a sensible approach to develop small molecular inhibitors that target SpAdK-mediated encapsulation to prevent pneumococcal infection.
Electronic supplementary material
Acknowledgements
This work was supported by a grant from the National Research Foundation (NRF-2015R1 A2 A1 A10052511) to D.-K.R.
Conflict of interest
The authors declare that they have no conflict of interest.
Footnotes
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
These authors contributed equally: Prachetash Ghosh, Truc Thanh Luong
Electronic supplementary material
Supplementary information accompanies this paper at 10.1038/s12276-018-0141-y.
References
- 1.Mitchell TJ. Virulence factors and the pathogenesis of disease causedby Streptococcus pneumoniae. Res. Microbiol. 2000;151:413–419. doi: 10.1016/S0923-2508(00)00175-3. [DOI] [PubMed] [Google Scholar]
- 2.Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat. Rev. Micro. 2008;6:288–301. doi: 10.1038/nrmicro1871. [DOI] [PubMed] [Google Scholar]
- 3.Thach TT, Luong TT, Lee S, Rhee DK. Adenylate kinase from Streptococcus pneumoniae is essential for growth through its catalytic activity. FEBS Open Bio. 2014;4:672–682. doi: 10.1016/j.fob.2014.07.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Hammerschmidt S, et al. Illustration of pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells. Infect. Immun. 2005;73:4653–4667. doi: 10.1128/IAI.73.8.4653-4667.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.López R, García E. Recent trends on the molecular biology of pneumococcal capsules, lytic enzymes, and bacteriophage. FEMS Microbiol. Rev. 2004;28:553–580. doi: 10.1016/j.femsre.2004.05.002. [DOI] [PubMed] [Google Scholar]
- 6.Morona JK, Miller DC, Morona R, Paton JC. The effect that mutations in the conserved capsular polysaccharide biosynthesis genes cpsA, cpsB, and cpsD have on virulence of Streptococcus pneumoniae. J. Infect. Dis. 2004;189:1905–1913. doi: 10.1086/383352. [DOI] [PubMed] [Google Scholar]
- 7.Wu K, et al. CpsR, a GntR family regulator, transcriptionally regulates capsular polysaccharide biosynthesis and governs bacterial virulence in Streptococcus pneumoniae. Sci. Rep. 2016;6:29255. doi: 10.1038/srep29255. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Bentley SD, et al. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS. Genet. 2006;2:e31. doi: 10.1371/journal.pgen.0020031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Garcia E, Llull D, Munoz R, Mollerach M, Lopez R. Current trends in capsular polysaccharide biosynthesis of Streptococcus pneumoniae. Res. Microbiol. 2000;151:429–435. doi: 10.1016/S0923-2508(00)00173-X. [DOI] [PubMed] [Google Scholar]
- 10.Yother J. Capsules of Streptococcus pneumoniae and other bacteria: paradigms for polysaccharide biosynthesis and regulation. Annu. Rev. Microbiol. 2011;65:563–581. doi: 10.1146/annurev.micro.62.081307.162944. [DOI] [PubMed] [Google Scholar]
- 11.Morona JK, Morona R, Miller DC, Paton JC. Mutational analysis of the carboxy-terminal (YGX)4 repeat domain of CpsD, an autophosphorylating tyrosine kinase required for capsule biosynthesis in Streptococcus pneumoniae. J. Bacteriol. 2003;185:3009–3019. doi: 10.1128/JB.185.10.3009-3019.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Shainheit MG, Mulé M, Camilli A. The core promoter of the capsule operon of Streptococcus pneumoniae is necessary for colonization and invasive disease. Infect. Immun. 2014;82:694–705. doi: 10.1128/IAI.01289-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Aanensen DM, Mavroidi A, Bentley SD, Reeves PR, Spratt BG. Predicted functions and linkage specificities of the products of the Streptococcus pneumoniae capsular biosynthetic loci. J. Bacteriol. 2007;189:7856–7876. doi: 10.1128/JB.00837-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Bender MH, Cartee RT, Yother J. Positive correlation between tyrosine phosphorylation of CpsD and capsular polysaccharide production in Streptococcus pneumoniae. J. Bacteriol. 2003;185:6057–6066. doi: 10.1128/JB.185.20.6057-6066.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Haase GH, et al. Adenylate kinases from thermosensitive Escherichia coli strains. J. Mol. Biol. 1989;207:151–162. doi: 10.1016/0022-2836(89)90446-4. [DOI] [PubMed] [Google Scholar]
- 16.van Horssen R, et al. Modulation of cell motility by spatial repositioning of enzymatic ATP/ADP exchange capacity. J. Biol. Chem. 2009;284:1620–1627. doi: 10.1074/jbc.M806974200. [DOI] [PubMed] [Google Scholar]
- 17.Dzeja P, Terzic A. Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing. Int. J. Mol. Sci. 2009;10:1729–1772. doi: 10.3390/ijms10041729. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Echlin H, et al. Pyruvate oxidase as a critical link between metabolism and capsule biosynthesis in Streptococcus pneumoniae. PLoS Pathog. 2016;12:e1005951. doi: 10.1371/journal.ppat.1005951. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Mahdi LK, Van der Hoek MB, Ebrahimie E, Paton JC, Ogunniyi AD. Characterization of Pneumococcal Genes Involved in Bloodstream Invasion in a Mouse Model. PLoS ONE. 2015;10:e0141816. doi: 10.1371/journal.pone.0141816. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Croucher NJ, et al. Rapid pneumococcal evolution in response to clinical interventions. Science. 2011;331:430–434. doi: 10.1126/science.1198545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Carter R, et al. Genomic analyses of pneumococci from children with sickle cell disease expose host-specific bacterial adaptations and deficits in current interventions. Cell. Host. Microbe. 2014;15:587–599. doi: 10.1016/j.chom.2014.04.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Hathaway LJ, et al. Capsule type of Streptococcus pneumoniae determines growth phenotype. PLoS Pathog. 2012;8:e1002574. doi: 10.1371/journal.ppat.1002574. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Carvalho SM, Kloosterman TG, Kuipers OP, Neves AR. CcpA ensures optimal metabolic fitness of Streptococcus pneumoniae. PLoS ONE. 2011;6:e26707. doi: 10.1371/journal.pone.0026707. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Ogunniyi AD, Giammarinaro P, Paton JC. The genes encoding virulence-associated proteins and the capsule of Streptococcus pneumoniae are upregulated and differentially expressed in vivo. Microbiol. 2002;148(Pt 7):2045–2053. doi: 10.1099/00221287-148-7-2045. [DOI] [PubMed] [Google Scholar]
- 25.Morrison DA, Lacks SA, Guild WR, Hageman JM. Isolation and characterization of three new classes of transformation-deficient mutants of Streptococcus pneumoniae that are defective in DNA transport and genetic recombination. J. Bacteriol. 1983;156:281–290. doi: 10.1128/jb.156.1.281-290.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Avery OT, MacLeod CM, McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J. Exp. Med. 1944;79:137–158. doi: 10.1084/jem.79.2.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Luong TT, et al. Ethanol-induced alcohol dehydrogenase E (AdhE) potentiates pneumolysin in Streptococcus pneumoniae. Infect. Immun. 2014;IAI:02434–02414. doi: 10.1128/IAI.02434-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Morona JK, Morona R, Paton JC. Attachment of capsular polysaccharide to the cell wall of Streptococcus pneumoniae type 2 is required for invasive disease. Proc. Natl. Acad. Sci. USA. 2006;103:8505–8510. doi: 10.1073/pnas.0602148103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Xayarath B, Yother J. Mutations blocking side chain assembly, polymerization, or transport of a Wzy-dependent Streptococcus pneumoniae capsule are lethal in the absence of suppressor mutations and can affect polymer transfer to the cell wall. J. Bacteriol. 2007;189:3369–3381. doi: 10.1128/JB.01938-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Yang J, et al. The I-TASSER Suite: protein structure and function prediction. Nat. Methods. 2015;12:7–8. doi: 10.1038/nmeth.3213. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Chen R, Li L, Weng Z. ZDOCK: an initial-stage protein-docking algorithm. Proteins. 2003;52:80–87. doi: 10.1002/prot.10389. [DOI] [PubMed] [Google Scholar]
- 32.Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ. PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res. 2005;33(Web Server issue):W363–W367. doi: 10.1093/nar/gki481. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Andrusier N, Nussinov R, Wolfson HJ. FireDock: fast interaction refinement in molecular docking. Proteins. 2007;69:139–159. doi: 10.1002/prot.21495. [DOI] [PubMed] [Google Scholar]
- 34.Rigsby RE, Parker AB. Using the PyMOL application to reinforce visual understanding of protein structure. Biochem Mol. Biol. Educ. 2016;44:433–437. doi: 10.1002/bmb.20966. [DOI] [PubMed] [Google Scholar]
- 35.Morona JK, Paton JC, Miller DC, Morona R. Tyrosine phosphorylation of CpsD negatively regulates capsular polysaccharide biosynthesis in Streptococcus pneumoniae. Mol. Microbiol. 2000;35:1431–1442. doi: 10.1046/j.1365-2958.2000.01808.x. [DOI] [PubMed] [Google Scholar]
- 36.Kinoshita E, Kinoshita-Kikuta E, Koike T. Advances in Phos-tag-based methodologies for separation and detection of the phosphoproteome. Biochim. Biophys. Acta. 2015;1854:601–608. doi: 10.1016/j.bbapap.2014.10.004. [DOI] [PubMed] [Google Scholar]
- 37.Olivares-Illana V, et al. Structural basis for the regulation mechanism of the tyrosine kinase CapB from Staphylococcus aureus. PLoS Biol. 2008;6:e143. doi: 10.1371/journal.pbio.0060143. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Fisslthaler B, Loot AE, Mohamed A, Busse R, Fleming I. Inhibition of endothelial nitric oxide synthase activity by proline-rich tyrosine kinase 2 in response to fluid shear stress and insulin. Circ. Res. 2008;102:1520–1528. doi: 10.1161/CIRCRESAHA.108.172072. [DOI] [PubMed] [Google Scholar]
- 39.Chaves-Sanjuan A, et al. Structural basis of the regulatory mechanism of the plant CIPK family of protein kinases controlling ion homeostasis and abiotic stress. Proc. Natl. Acad. Sci. USA. 2014;111:E4532–E4541. doi: 10.1073/pnas.1407610111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Bechet E, et al. Identification of structural and molecular determinants of the tyrosine-kinase Wzc and implications in capsular polysaccharide export. Mol. Microbiol. 2010;77:1315–1325. doi: 10.1111/j.1365-2958.2010.07291.x. [DOI] [PubMed] [Google Scholar]
- 41.Deutscher J, Saier MH., Jr. Ser/Thr/Tyr protein phosphorylation in bacteria - for long time neglected, now well established. J. Mol. Microbiol. Biotechnol. 2005;9:125–131. doi: 10.1159/000089641. [DOI] [PubMed] [Google Scholar]
- 42.Vincent C, et al. Relationship between exopolysaccharide production and protein-tyrosine phosphorylation in Gram-negative bacteria. J. Mol. Biol. 2000;304:311–321. doi: 10.1006/jmbi.2000.4217. [DOI] [PubMed] [Google Scholar]
- 43.Soulat D, et al. Staphylococcus aureus operates protein-tyrosine phosphorylation through a specific mechanism. J. Biol. Chem. 2006;281:14048–14056. doi: 10.1074/jbc.M513600200. [DOI] [PubMed] [Google Scholar]
- 44.Wugeditsch T, et al. Phosphorylation of Wzc, a tyrosine autokinase, is essential for assembly of group 1 capsular polysaccharides in Escherichia coli. J. Biol. Chem. 2001;276:2361–2371. doi: 10.1074/jbc.M009092200. [DOI] [PubMed] [Google Scholar]
- 45.Niemeyer D, Becker A. The molecular weight distribution of succinoglycan produced by Sinorhizobium meliloti is influenced by specific tyrosine phosphorylation and ATPase activity of the cytoplasmic domain of the ExoP protein. J. Bacteriol. 2001;183:5163–5170. doi: 10.1128/JB.183.17.5163-5170.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Grangeasse C, Doublet P, Cozzone AJ. Tyrosine phosphorylation of protein kinase Wzc from Escherichia coli K12 occurs through a two-step process. J. Biol. Chem. 2002;277:7127–7135. doi: 10.1074/jbc.M110880200. [DOI] [PubMed] [Google Scholar]
- 47.Weiser JN, et al. Changes in availability of oxygen accentuate differences in capsular polysaccharide expression by phenotypic variants and clinical isolates of Streptococcus pneumoniae. Infect. Immun. 2001;69:5430–5439. doi: 10.1128/IAI.69.9.5430-5439.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Geno KA, Hauser JR, Gupta K, Yother J. Streptococcus pneumoniae phosphotyrosine phosphatase CpsB and alterations in capsule production resulting from changes in oxygen availability. J. Bacteriol. 2014;196:1992–2003. doi: 10.1128/JB.01545-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Wu HY, et al. Establishment of a Streptococcus pneumoniae nasopharyngeal colonization model in adult mice. Microb. Pathog. 1997;23:127–137. doi: 10.1006/mpat.1997.0142. [DOI] [PubMed] [Google Scholar]
- 50.Talbot UM, Paton AW, Paton JC. Uptake of Streptococcus pneumoniae by respiratory epithelial cells. Infect. Immun. 1996;64:3772–3777. doi: 10.1128/iai.64.9.3772-3777.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Kim JO, et al. Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae. Infect. Immun. 1999;67:2327–2333. doi: 10.1128/iai.67.5.2327-2333.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Kim JO, Weiser JN. Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae. J. Infect. Dis. 1998;177:368–377. doi: 10.1086/514205. [DOI] [PubMed] [Google Scholar]
- 53.Novak R, Henriques B, Charpentier E, Normark S, Tuomanen E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature. 1999;399:590–593. doi: 10.1038/21202. [DOI] [PubMed] [Google Scholar]
- 54.Hyams C, Camberlein E, Cohen JM, Bax K, Brown JS. The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infect. Immun. 2010;78:704–715. doi: 10.1128/IAI.00881-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Sheffield P, Garrard S, Derewenda Z. Overcoming expression and purification problems of RhoGDI using a family of “parallel” expression vectors. Protein Expr. Purif. 1999;15:34–39. doi: 10.1006/prep.1998.1003. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.